1448313-15-2

Upstream product

• 1355454-27-1 tert-butyl 4-(2-(3-aminophenyl)-7-oxo-7H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-yl)piperazine-1-carboxylate 
• 1599424-55-1 tert-butyl 4-(2-(3-(2-(tert-butoxycarbonylamino)-acetamido)-5-(1,2-dihydroxyethan-1-yl)phenyl)-5-oxo-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-7-yl)piperazine-1-carboxylate 
• 1448313-14-1 tert-butyl 4-(2-(3-(2-(tert-butoxycarbonylamino)acetamido)-5-vinylphenyl)-7-oxo-7H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-yl)piperazine-1-carboxylate 
• 1567346-28-4 tert-butyl 4-(2-(3-amino-5-vinylphenyl)-7-oxo-7H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-yl)piperazine-1-carboxylate 

Downstream Products

• 1448313-16-3 tert-butyl 4-(2-(3-(2-((tert-butoxycarbonyl)amino)acetamido)-5-(hydroxymethyl)phenyl)-7-oxo-7H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-yl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of thrombotic disorders

The present invention relates to compounds and compositions of Formula P useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The definitions of variables A, B, R2, R3, R4, Ra, Ra′, Rb, Rb′, Rc, Rd, Rd′, Re, and Re′ are provided in the disclosure. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.

A novel class of ion displacement ligands as antagonists of the αiIbβ3 receptor that limit conformational reorganization of the receptor

A collection of αIIbβ3 integrin receptor antagonists possessing a unique MIDAS metal ion displacement mechanism of action is presented. Insight into these agents' structure-activity relationships, binding modality, and pharmacokinetic and pharmacodynamic